BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval

Dow Jones11-27

By Adriano Marchese

BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers.

The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.

The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy.

The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without.

These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer cases are projected in 2040, an increase of nearly 60% from 2020, the company said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

November 27, 2024 06:30 ET (11:30 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486784762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486784762","market":"other","top_or_hot":-1,"title":"BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers. \n</p>\n<p>\n  The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. \n</p>\n<p>\n  The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy. \n</p>\n<p>\n  The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without. \n</p>\n<p>\n  These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer cases are projected in 2040, an increase of nearly 60% from 2020, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 27, 2024 06:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adriano Marchese \n\n\n \n\n\n  BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers. \n\n\n  The European Commission approved ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1500","symbol_name":"做空集合股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486784762","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486784762","pubTimestamp":1732707000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers.The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy.The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without.These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1500":"做空集合股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","06160":"百济神州","BK1583":"高瓴概念","BK1588":"回港中概股","BK4535":"淡马锡持仓","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4588":"碎股","BK4526":"热门中概股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4156":"煤与消费用燃料","BK1161":"生物科技","BK4505":"高瓴资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BGNE":"百济神州"},"translate_title":"百济神州胃癌、食道癌治疗获得欧盟批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1,"06160":1},"content_text":"By Adriano Marchese \n\n\n \n\n\n  BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers. \n\n\n  The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. \n\n\n  The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy. \n\n\n  The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without. \n\n\n  These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer cases are projected in 2040, an increase of nearly 60% from 2020, the company said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 27, 2024 06:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486784762"}